Discriminative-stimulus effects of NS9283, a nicotinic α4β 2*positive allosteric modulator, in nicotine-discriminating rats

Psychopharmacology

Volumn 231, Issue 1, 2014, Pages 67-74

  Mohler, Eric G ^a   Franklin, Stanley R ^a   Rueter, Lynne E ^a  

^a ABBVIE INC   (United States)

Author keywords

4 2; Drug discrimination; Nicotine; Nicotine agonist; Nicotinic acetylcholine receptor; Positive allosteric modulator; Rat; receptor

Indexed keywords

3 [3 (PYRIDINE 3 YL) 1,2,4 OXADIAZOL 5 YL]BENZONITRILE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; NS 9283; TEBANICLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION TEST; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; IN VIVO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; STIMULUS GENERALIZATION;

ALLOSTERIC REGULATION; ANIMALS; AZETIDINES; CHOLINERGIC AGENTS; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; GENERALIZATION (PSYCHOLOGY); MALE; NICOTINE; NICOTINIC AGONISTS; OXADIAZOLES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

EID: 84891825820     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3207-5     Document Type: Article

References (43)

1. Albuquerque EX, Pereira EFR, Alkondon M, Rodgers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89:73-120
2. Allison C, Shoaib M (2013) Nicotine improves performance in an attention set shifting task in rats. Neuropharmacology 64:314-320
3. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M, Arneric SP (1998) Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 279:77-81.
4. Bertrand D, Gopalakrishnan M (2007) Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 74:1155-1163
5. Brioni JD, Kim DJB, O-Neill AB (1996) Nicotine cue: lack of effect of the alpha 7 nicotinic receptor antagonist methyllycaconitine. Eur J Pharmacol 301:1-5
6. Changeux JP (2010) Allosteric receptors: from electric organ to cognition. Annu Rev Pharmacol Toxicol 50:1-38
7. Dani JA, Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699-729
8. Damaj MI, Fonck C, Marks MJ, Deshpande P, Labarca C, Lester HA, Collins AC, Martin BR (2007) Genetic approaches identify differential roles for α4β2*nicotinic receptors in acute models of antinociception in mice. J Pharmacol Exp Ther 321:1161-1169
9. Donnelly-Roberts D, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Walczak J, Holladay MW, Williams M, Arneric SP (1998) ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. J Pharmacol Exp Ther 285:777-786
10. Exley R, Maubourguet N, David V, Eddine R, Evrard A, Pons S, Marti F, Threlfell S, Cazala P, McIntosh JM, Changeux J-P, Maskos U, Cragg SJ, Faure P (2011) Distinct contributions of nicotinic acetylcholine receptor subunit α4 and subunit α6 to the reinforcing effects of nicotine. PNAS 108(18):7577-7582
11. Faghih R, Gopalakrishnan M, Briggs CA (2008) Allosteric modulators of the α7 nicotine acetylcholine receptor. J Med Chem 51(4):701-712
12. Faghih R, Gopalakrishnan M, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C, Ween H, Curtis MP, Sarris KA, Gfesser GA et al (2009) Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl-benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the α7 nicotinic acetylcholine receptor. J Med Chem 52:3377-3384
13. Gommans J, Stolerman IP, Shoaib M (2000) Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice. Neuropharmacology 39:2840-2847
14. Grottick AJ, Haman M, Wyler R, Higgins GA (2003) Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology 28:880-887
15. Hahn B, Sharples CGV, Wonnacott S, Shoaib M, Stolerman IP (2003) Attentional effects of nicotinic agonists in rats. Neuropharmacology 44:1054-1067
16. Hahn B, Stolerman IP (2002) Nicotine-induced attentional enhancement in rats: Effects of chronic exposure to nicotine. Neuropsychopharmacology 27:712-722
17. Hurst RS, Hajós M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann WE, Piotrowski DW, Groppi VE, Allaman G, Ogier R, Bertrand S, Bertrand D, Arneric SP (2005) A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25(17):4396-4405
18. Ji J, Bunnelle WH, Anderson DJ, Faltynek C, Dyhring T, Ahring PK, Rueter LE, Curzon P et al (2007) A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane α4β2*nicotinic acetylcholine receptor selective agonist: synthesis, analgesic efficacy and tolerability profile in animal models. Biochem Pharmacol 74:1253-1262
19. Kim JS, Padnya A, Weltzin M, Edmonds BW, Schulte MK, Glennon RA (2007) Synthesis of desformylflustrabromine and its evaluation as an α4β2*and α7 nACh receptor modulator. Bioorg Med Chem Lett 17(17):4855-4860
20. Lee C-H, Zhu C, Malyszm H, Campbell T, Shaughnessy T, Honore P, Polakowski J, Gopalakrishnan M (2011) α4β2*neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2*nAChR agonists in pain. Biochem Pharmacol 82:959-966
21. Levin ED, McClernon FJ, Rezvani AH (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharm 184:523-539
22. Lilienfeld S (2002) Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev 8:159-176
23. Maelicke A, Albuquerque EX (1996) New approach to drug therapy in Alzheimer's disease. Drug Discov Today 1:53-59
24. Maelicke A, Albuquerque EX (2000) Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393:165-170
25. Malysz J, Dyhring PK, Ahring GM, Olsen D, Peters D, Gronlien JG, Wetterstrand H, Ween M, Haakerud M, Thorin-Hagene K, Andersen E, Anderson DJ, Hu M, Kroeger PE, Lee C-H, Gopalakrishnan M, Timmerman DB (2009a) In vitro pharmacological profile of a novel α4β2*positive allosteric modulator NS9283 (A-969933). Biochem Pharmacol 78:919-920
26. Malysz J, Gronlien JH, Anderson DJ, Haakerud M, Thorin-Hagene K, Ween H, Wetterstrand C, Briggs CA et al (2009b) In vitro pharmacological characterization of a novel allosteric modulator of α7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1- yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile. J Pharmacol Exp Ther 330:257-267
27. Mohler EG, Franklin SR, Rueter LE, Fox GB, Decker MW, Browman KE (2010) ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects. Pharmacol Biochem Behav 95:146-157
28. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Merlo-Pich E, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the beta-2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177
29. Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, Perez XA (2009) Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 78:677-685
30. Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG (2010) Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Current Pharm Design 16:309-322
31. Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (2007) Central nicotinic receptors: structure, function, ligands, and therapeutic potential. Chem Med Chem 2:746-767
32. Schilström B, Ivanov VB, Wiker C, Svensson TH (2007) Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacol 32:43-53
33. Shoaib M, Gommans J, Morley A, Stolerman IP, Grailhe R, Changeux J-P (2002) The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion. Neuropharmacology 42:530-539
34. Shoaib M, Zubaran C, Stolerman IP (2000) Antagonism of stimulus properties of nicotine by dihydro-beta-erythroidine (DHbetaE) in rats. Psychopharmacology (Berl) 149(2):140-146
35. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, Tricklebank M (2007) Ligands selective for α4β2*but not α3β4 or α7 nicotinic receptors generalize to the nicotine discriminative stimulus in the rat. Psychopharmacology 190:157-170
36. Smith JW, Stolerman IP (eds) (2009) Nicotine psychopharmacology. Handbook of psychopharmacology, vol 192. Springer, 295, pp 295-333
37. Stolerman IP, Chamberlain S, Bizarro L, Fernandes C, Schalkwyk L (2004) The role of nicotinic receptor alpha 7 subunits in nicotine discrimination. Neuropharmacology 46:363-371
38. Stolerman IP, Chandler CJ, Garcha HS, Newton JM (1999) Selective antagonism of behavioural effects of nicotine by dihydro-beta-erythroidine in rats. Psychopharm 129:390-397
39. Stolerman IP, Rasul F, Shine PJ (1989) Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987. Psychopharmacology 98:1-19
40. Timmermann DB, Sandager-Nielsen K, Dyhring T, Smith M, Jacobsen AM, Nielsen EO, Grunnet M, Christensen JK, Peters D, Kohlhaas K, Olsen GM, Ahring PK (2012) Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors. Br J Pharmacol 167:164-182
41. Tuesta LM, Fowler CD, Kenny PJ (2011) Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem Pharmacol 82:984-995
42. van Haaren F, Anderson KG, Haworth SC, Kem WR (1999) GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue. Pharmacol Biochem Behav 64:439-444
43. Zaniewska M, McCreary AC, Przegaliński E, Filip M (2006) Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine. Eur J Pharmacol 540:96-106